Qualigen Therapeutics (QLGN) shares soared about 200% on Monday at the peak after the biotech company secured a $41 million investment from Faraday Future (FFAI) and its founder YT Jia.
Investors cheered QLGN also because it’s rebranding as CXC10 as part of a major pivot into crypto-Web3, revealing three growth engines: a crypto treasury, a DeAI trading platform, and ecosystem tokens.
QLGN stock has since reversed much of the post-announcement gains, but is still trading up nearly 190% from its YTD lows at the time of writing.
Why Faraday Investment and Crypto Pivot Matter for QLGN Stock
FFAI’s majority stake triggered a sharp increase in Qualigen Therapeutics stock primarily because it signals serious intent, not just passive interest.
With Faraday owning 55% and Jia adding another 7% under a two-year lockup, the partnership brings both credibility and runway to the newly rebranded CXC10.
Meanwhile, the crypto and Web3 pivot adds speculative upside, especially with early gains from the C10 treasury and the promise of AI-driven trading via BesTrade.
For retail investors, this could be a moonshot narrative – EV meets DeAI meets tokenomics. But it’s also a radical departure from the company’s biotech roots, raising questions about execution and the long-term viability of QLGN stock.
QLGN Shares Remain a High-Risk Bet for the Remainder of 2025
While the rebranding and crypto enthusiasm sure has reignited investor interest in QLGN shares, the company’s financials remain rather bleak in the second half of 2025.
Qualigen Therapeutics has a history of operating losses, limited revenue, and a strained balance sheet that raises the risk of dilution. Its biotech legacy offers little synergy with Web3, making the pivot feel more opportunistic than strategic.
Valuation is hard to justify as well given the lack of proven product-market fit in crypto and the 7% gain on its treasury is hardly conclusive.
All in all, regulatory uncertainty, execution risk, and speculative froth make QLGN stock a high-risk bet. Long-term investors may want to wait for real traction before jumping in, especially since Qualigen Therapeutics doesn’t currently receive coverage from Wall Street analysts.
